4-[2-Methyl-5-(2-morpholinopyridine-4-carboxamido)anilino]-5-methylthieno[2,3-d]pyrimidine | 295776-71-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[2-Methyl-5-(2-morpholinopyridine-4-carboxamido)anilino]-5-methylthieno[2,3-d]pyrimidine
• 英文别名: N-[4-methyl-3-[(5-methylthieno[2,3-d]pyrimidin-4-yl)amino]phenyl]-2-morpholin-4-ylpyridine-4-carboxamide
• CAS: 295776-71-5
• 化学式: C₂₄H₂₄N₆O₂S
• 分子量: 460.56
• InChiKey: OVRGQJVRMLLGKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  N-(3-amino-4-methylphenyl)-2-morpholinopyridine-4-carboxamide 、 4-氯-5-甲基噻吩并[2,3-d]嘧啶 在 2-甲基戊烷 、 乙醚 作用下， 以 异丙醇 为溶剂， 反应 18.0h， 以There was thus obtained the title compound (0.021 g)的产率得到4-[2-Methyl-5-(2-morpholinopyridine-4-carboxamido)anilino]-5-methylthieno[2,3-d]pyrimidine
  参考文献：
  名称：

  Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease

  摘要：

  本发明涉及一种公式(I)的双环化合物，其中：G为N、CH或C(CN)；环X为含有1、2或3个来自氧、硫和氮的杂原子的5-或6元融合杂芳基环；m为0-2；R1为羟基、卤素、三氟甲基、氰基、巯基、硝基、氨基、羧基和氨基甲酰等基团；R2和R3中的每一个都是氢、卤素、C1-6烷基、C2-6烯基或C2-6炔基；R4为氢、羟基、C1-6烷基、C1-6烷氧基、氨基和N-C1-6烷基氨基等基团；R5为氢、卤素、三氟甲基、氰基、硝基、氨基和羟基等基团，q为0-4；或其药学上可接受的盐或体内可水解酯；以及其制备方法、包含它的制药组合物和在治疗由细胞因子介导的疾病或医疗状况中的应用。

  公开号：

  US06784174B1

文献信息

• PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASE
  申请人：AstraZeneca AB

  公开号：EP1165566B1

  公开（公告）日：2003-08-20
• US6784174B1
  申请人：——

  公开号：US6784174B1

  公开（公告）日：2004-08-31
• [EN] PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASE<br/>[FR] DERIVES DE PYRIDINE ET DE PYRIMIDINE ET LEUR UTILISATION COMME INHIBITEURS DE MALADIES ASSOCIEES A LA CYTOKINE
  申请人：ASTRAZENECA AB

  公开号：WO2000056738A1

  公开（公告）日：2000-09-28

  This invention concerns a bicyclic compound of Formula (I), wherein: G is N, CH or C(CN); ring X is a 5- or 6-membered fused heteroaryl ring which contains 1, 2, or 3 heteroatoms selected from oxygen, sulphur and nitrogen; m is 0 - 2; R1 is a group such as hydroxy, halo, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; each of R?2 and R3¿ is hydrogen, halo, C¿1-6?alkyl, C2-6alkenyl or C2-6alkynyl; R?4¿ is a group such as hydrogen, hydroxy, C¿1-6?alkyl, C1-6alkoxy, amino and N-C1-6alkylamino; R?5¿ is a group such as hydrogen, halo, trifluoromethyl, cyano, nitro, amino and hydroxy, and q is 0 - 4; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof; processes for its preparation, a pharmaceutical composition containing it and its use in the treatment of diseases or medical conditions mediated by cytokines.
• Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
  申请人：AstraZeneca AB

  公开号：US06784174B1

  公开（公告）日：2004-08-31

  This invention concerns a bicyclic compound of Formula (I), wherein: G is N, CH or C(CN); ring X is a 5- or 6-membered fused heteroaryl ring which contains 1, 2, or 3 heteroatoms selected from oxygen, sulphur and nitrogen; m is 0-2; R1 is a group such as hydroxy, halo, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; each of R2 and R3 is hydrogen, halo, C1-6alkyl, C2-6alkenyl or C2-6 alkynyl; R4 is a group such as hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy, amino and N-C1-6alkylamino; R5 is a group such as hydrogen, halo, trifluoromethyl, cyano, nitro, amino and hydroxy, and q is 0-4; or a pharmaceutically acceptable salt or an in vivo cleavable ester thereof; processes for its preparation, a pharmaceutical composition containing it and its use in the treatment of diseases or medical conditions mediated by cytokines.

  本发明涉及一种公式(I)的双环化合物，其中：G为N、CH或C(CN)；环X为含有1、2或3个来自氧、硫和氮的杂原子的5-或6元融合杂芳基环；m为0-2；R1为羟基、卤素、三氟甲基、氰基、巯基、硝基、氨基、羧基和氨基甲酰等基团；R2和R3中的每一个都是氢、卤素、C1-6烷基、C2-6烯基或C2-6炔基；R4为氢、羟基、C1-6烷基、C1-6烷氧基、氨基和N-C1-6烷基氨基等基团；R5为氢、卤素、三氟甲基、氰基、硝基、氨基和羟基等基团，q为0-4；或其药学上可接受的盐或体内可水解酯；以及其制备方法、包含它的制药组合物和在治疗由细胞因子介导的疾病或医疗状况中的应用。